|
USA-ME-BOOTHBAYHARBOR شركة الأدلة
|
شركة أخبار :
- Prostate-Specific Antigen (PSA) Test - NCI - National Cancer Institute
Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland Both prostate cancer and several benign conditions (particularly benign prostatic hyperplasia, or BPH, and prostatitis) can cause PSA levels in the blood to rise The PSA test measures the level of PSA in the blood
- Prueba del antígeno prostático específico (PSA)
El antígeno prostático específico o PSA es una proteína que producen tanto las células normales como las células malignas (cancerosas) de la próstata Tanto el cáncer de próstata como varias afecciones benignas (en particular la hiperplasia prostática benigna, o HPB, y la prostatitis) hacen que aumenten las concentraciones del PSA en la sangre
- Understanding Prostate Changes and Conditions - National Cancer Institute
prostate cancer; Learn more about the PSA test What is prostatitis? Prostatitis is a benign condition that involves inflammation of the prostate Prostatitis does not increase your risk of prostate cancer It is the most common urinary condition in men younger than age 50 and affects at least half of all men at some time during their lives
- Prostate Cancer Screening - NCI - National Cancer Institute
A prostate cancer gene 3 (PCA3) RNA test may be used for certain patients If a man had a high PSA level and a biopsy of the prostate did not show cancer and the PSA level remains high after the biopsy, a PCA3 RNA test may be done This test measures the amount of PCA3 RNA in the urine after a DRE
- Prostate Cancer Treatment - NCI - National Cancer Institute
Prostate cancer treatment can include active surveillance, surgery, radiation therapy, hormonal therapy, chemotherapy, immunotherapy, and supportive care Learn more about treatment options for prostate cancer in this expert-reviewed summary PSA is a substance made by the prostate that may be found in higher than normal amounts in the
- Prostate Cancer Prevention - NCI
Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate The prostate is a gland in the male reproductive system The prostate is just below the bladder (the organ that collects and empties urine) and in front of the rectum (the lower part of the intestine) It is about the size of a walnut and surrounds part of the urethra (the tube that empties urine
- Hormone Therapy for Prostate Cancer Fact Sheet - NCI
An increase in PSA level may indicate that a man’s cancer has started growing again or become resistant to the hormone therapy that is currently being used Prostate Cancer and Prostatic Diseases 2007; 10(4):340–346 [PubMed Abstract] Related Resources Cancer Fatigue
- Prostate Cancer Screening (PDQ®) - NCI - National Cancer Institute
The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) The CAP trial of PSA screening was conducted in the United Kingdom This was a primary care–based cluster randomized trial of an invitation to a single PSA test, followed by standardized prostate biopsy in men with PSA levels of 3 ng mL or higher The trial was designed to
- Xtandi Approved for High-Risk Prostate Cancer - NCI
In a study presented in June 2023 at American Society of Clinical Oncology annual meeting, in fact, researchers showed that, based on PSMA-PET findings, many people with biochemical recurrences with rapid PSA doubling times actually had small tumors either in and around the prostate or elsewhere in the body Use of PSMA-PET has expanded rapidly in the United States, so questions have been
- PSA Velocity Does Not Improve Prostate Cancer Detection
Adapted from the NCI Cancer Bulletin A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24, 2011, in the Journal of the National Cancer Institute The rate of change in PSA levels, referred to as PSA velocity, has been studied as a marker for the presence of prostate cancer
|
|